Mark R Litzow is an expert in Hematology at Mayo Clinic (United States, Rochester) (United States). As of October 2026, ScienceLeadR ranks Mark R Litzow in the top 1% of experts worldwide for Leukemia, Bone Marrow Transplantation and Stem Cell Transplantation. Mark R Litzow has authored 1,296 publications, the most recent in 2026, and is an investigator in 39 clinical trials, 1 of them ongoing. SLR score: 3,728 (community average: 125). How the SLR is computed.

LeadR Profile

Mark R Litzow Mayo Clinic (United States, Rochester) United States
3 728 ScienceLeadR Reputation 3728
Network Map

Hematology

Subspecialties: Oncology - Transplantation - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1989 - 2026

Source: PubMed

Mayo Clinic (United States, Rochester)

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1296

Citations

Citations: 48 949 1st author: 27 Last author: 121 Unique author: 28


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study.
PMID 42832396 — cells, precursor cell lymphoblastic leukemia-lymphoma, leukemia, drug therapy, therapeutics, enhancer elements, genetic, mutation, chemotherapy
Blood20260
Allogeneic hematopoietic stem cell transplantation rather than specific front-line therapy is associated with long-term survival in blastic plasmacytoid dendritic cell neoplasm: the Mayo Clinic experience.
PMID 42817843 — cells, hematology, microscopy, electron, scanning transmission, hematopoietic stem cell transplantation, neoplasms, stem cells, therapeutics, dendritic cells, cell transplantation, stem cell transplantation, hematopoietic stem cells, transplantation
Haematologica20260
Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients.
PMID 42755126 — hematology, leukemia, leukemia, myeloid, acute, leukemia, myeloid, transplants, therapeutics, karyotype, mutation
Am J Hematol20260
Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials.
PMID 42687832 — bone marrow, hematology, leukemia, biopsy, leukemia, myeloid, acute, leukemia, myeloid, therapeutics
Haematologica20260
Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients.
PMID 42499183 — cells, hematology, microscopy, electron, scanning transmission, bone marrow transplantation, leukemia, myelomonocytic, chronic, leukemia, stem cells, transplants, therapeutics
Am J Hematol20260

Clinical Studies 39

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Chair: 4

By phase:

Phase 3 14
Phase 2 12
Phase 1 5
Phase 1/Phase 2 4
N/A 2
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 27
Active not recruiting 7
Recruiting 2
No longer available 1
Terminated 1
Withdrawn 1

By type:

Interventional 38
Expanded Access 1

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 1
multicentric5to9 1
multicentricup10 30

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
NCT04710576 — safety, macrophages, macrophage colony-stimulating factor, graft vs host disease, transplants, bronchiolitis obliterans, therapeutics, antibody affinity, colony-stimulating factors, bronchiolitis, bronchiolitis obliterans syndrome
Phase 2Recruiting2021

LeadR Networks

Main global connection map